Evolent Health reaffirms FY2025 revenue guidance of $2.06B-$2.11B at William Blair conference

Evolent Health, Inc.

Reaffirms FY2025 revenue guidance of $2.06B-$2.11B and Adjusted EBITDA of $135M-$165M.
Q2 2025 revenue guidance reaffirmed at $440M-$470M; Adj EBITDA $33M-$40M.
Guidance unchanged from the May 8, 2025 press release; no new financial targets.

item 7.01

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-25-000069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.